136 related articles for article (PubMed ID: 19654297)
1. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.
Attar RM; Jure-Kunkel M; Balog A; Cvijic ME; Dell-John J; Rizzo CA; Schweizer L; Spires TE; Platero JS; Obermeier M; Shan W; Salvati ME; Foster WR; Dinchuk J; Chen SJ; Vite G; Kramer R; Gottardis MM
Cancer Res; 2009 Aug; 69(16):6522-30. PubMed ID: 19654297
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
3. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
4. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
[TBL] [Abstract][Full Text] [Related]
5. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
6. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
7. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
8. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of resistance to antiandrogen therapy.
Chen CD; Welsbie DS; Tran C; Baek SH; Chen R; Vessella R; Rosenfeld MG; Sawyers CL
Nat Med; 2004 Jan; 10(1):33-9. PubMed ID: 14702632
[TBL] [Abstract][Full Text] [Related]
10. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.
Guo C; Linton A; Kephart S; Ornelas M; Pairish M; Gonzalez J; Greasley S; Nagata A; Burke BJ; Edwards M; Hosea N; Kang P; Hu W; Engebretsen J; Briere D; Shi M; Gukasyan H; Richardson P; Dack K; Underwood T; Johnson P; Morell A; Felstead R; Kuruma H; Matsimoto H; Zoubeidi A; Gleave M; Los G; Fanjul AN
J Med Chem; 2011 Nov; 54(21):7693-704. PubMed ID: 21936524
[TBL] [Abstract][Full Text] [Related]
11. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
12. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
13. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
14. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
15. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
16. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
17. ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ; Wongvipat J; Joseph JD; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff ED; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert MR; Bonnefous C; Darimont B; Scher HI; Smith-Jones P; Klang M; Smith ND; De Stanchina E; Wu N; Ouerfelli O; Rix PJ; Heyman RA; Jung ME; Sawyers CL; Hager JH
Cancer Res; 2012 Mar; 72(6):1494-503. PubMed ID: 22266222
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.
Terada N; Shimizu Y; Yoshida T; Maeno A; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O
Prostate; 2010 Feb; 70(3):252-61. PubMed ID: 19790238
[TBL] [Abstract][Full Text] [Related]
19. Steroid derivatives as pure antagonists of the androgen receptor.
Gauthier S; Martel C; Labrie F
J Steroid Biochem Mol Biol; 2012 Oct; 132(1-2):93-104. PubMed ID: 22449547
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
